SteadyMed Ltd. (NASDAQ:STDY) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k

7 years ago

SteadyMed Ltd. (NASDAQ:STDY) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.

On November13, 2017, SteadyMed Ltd (the “Company”) issued a press release announcing its financial results for the quarter ended September30, 2017. A copy of this press release is attached hereto as Exhibit99.1.

The information in this Current Report on Form8-K, including Exhibit99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form8-K.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)On November10, 2017, Peter Noymer, Ph.D., our Executive Vice President and Chief Operating Officer, voluntarily resigned his position at the Company. Dr.Noymer’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit Number	ExhibitDescription
99.1	Press Release, dated November13, 2017

SteadyMed Ltd. ExhibitEX-99.1 2 a17-26408_1ex99d1.htm EX-99.1 Exhibit 99.1 SteadyMed Reports Third Quarter 2017 Financial Results and Provides Corporate Update SAN RAMON,…To view the full exhibit click here
About SteadyMed Ltd. (NASDAQ:STDY)
SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). It is also developing approximately two products for the treatment of post-surgical and acute pain in the home setting, which include bupivacaine PatchPump for local anesthesia post-surgery and ketorolac PatchPump for short-term management of moderately severe acute pain. Its product candidates are enabled by its PatchPump. Its Trevyent offers a way of administration of treprostinil for subcutaneous or intravenous treatment of PAH patients. The Company’s ketorolac At Home Patient Analgesia (AHPA) product candidate is used for the short-term (approximately five days) management of moderately severe acute pain that requires analgesia at the opioid level in a post-surgical setting.